A modern plan for treating hypertension

J H Laragh1

  • 1Cardiovascular Center, New York Hospital-Cornell Medical Center, NY 10021.

Insights

Essential hypertension is not a single disease but has two main causes: renin-mediated and sodium-volume-mediated vasoconstriction. Understanding these mechanisms allows for targeted drug therapies, improving treatment for hypertension.

Area of Science:

  • Cardiology
  • Nephrology
  • Pharmacology

Background:

  • Essential hypertension presents as a complex spectrum of pathophysiologic disturbances.
  • Distinguishing between different vasoconstrictor mechanisms is crucial for effective treatment.

Purpose of the Study:

  • To characterize the two primary vasoconstrictor mechanisms in essential hypertension: renin-mediated and sodium-volume-mediated.
  • To establish a rational basis for antihypertensive drug therapy and identify curable conditions.

Main Methods:

  • Identification and characterization of renin-mediated and sodium-volume-mediated vasoconstriction.
  • Classification of antihypertensive drugs based on their mechanism of action.

Main Results:

  • Two distinct vasoconstrictor mechanisms identified: one renin-mediated, the other sodium-volume mediated.
  • Five major drug classes identified for monotherapy: converting enzyme inhibitors, beta-blockers, diuretics, calcium-channel antagonists, and alpha-blockers.
  • Therapeutic strategies enable screening for curable renovascular disease and primary aldosteronism.

Conclusions:

  • Understanding the underlying mechanisms of essential hypertension allows for more targeted and rational drug selection.
  • Long-term monotherapy for essential hypertension is achievable with appropriate drug choices.
  • The goal of therapy is to minimize drug количество, dosage, and frequency for lifelong management.

Related Concept Videos

Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...
Antihypertensive Drugs: Vasodilators01:23

Antihypertensive Drugs: Vasodilators

Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Hypertension I: Introduction01:28

Hypertension I: Introduction

Hypertension is a widespread, long-term medical condition where blood pressure in the arteries remains elevated. It is characterized by systolic blood pressure readings of 130 mm Hg or above or diastolic blood pressure (DBP) readings of 80 mm Hg or higher. Unmanaged hypertension poses significant health risks, making the distinction between primary (or essential) hypertension and secondary hypertension crucial, as their management and implications vary.Primary HypertensionPrimary hypertension,...
Hypertension IV: Drug Therapy and Lifestyle Modifications01:28

Hypertension IV: Drug Therapy and Lifestyle Modifications

Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...